Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)

Introduction. Favipiravir is an antiviral compound that inhibits the RNA-dependent polymerase and possesses antiviral properties against RNA viruses, including SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2). The new drug Areplivir® Zinc as a combination of favipiravir (200 mg) and zinc...

Full description

Saved in:

Bibliographic Details
Main Authors:	T. N. Komarov, N. S. Bagaeva, K. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, V. S. Shcherbakova, K. Ya. Zaslavskaya, P. A. Bely, A. V. Taganov, I. E. Shohin
Format:	Article
Language:	Russian
Published:	LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2024-03-01
Series:	Разработка и регистрация лекарственных средств
Subjects:	favipiravir zinc covid-19 pharmacokinetics
Online Access:	https://www.pharmjournal.ru/jour/article/view/1769
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Phase I Pharmacokinetics Study of Drug Areplivir® Zinc (INN: Favipiravir + Zinc Gluconate) (LLC "PROMOMED RUS", Russia)

Similar Items